DAPA HF Trial In this trial 4,744 patients with New York Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less were randomized to receive either dapagliflozin 10 mg once daily or placebo for a median of 18.2 months (162)
[DOI] [PMC free article] [PubMed] [Google Scholar] 76.Biessels G.J., Verhagen C., Janssen J., van den Berg E., Zinman B., Rosenstock J., George J.T., Passera A., Schnaidt S., Johansen O.E., et al
Benefits include improved endothelial function, lower arterial stiffness, and more efficient oxygen delivery
Alzheimers is a heterogeneous disease with multiple subtypes, and GLP-1 approaches may only benefit those with prominent metabolic or vascular dysfunction
Many melanocytomas arise within a preexisting nevus, due to the acquisition of a secondary pathogenic mutation in a single melanocyte which leads to subclonal outgrowth and distinct histopathologic features resulting in a so-called combined nevus
Pancreatitis: Inflammation of the pancreas has been reported